206 related articles for article (PubMed ID: 35256598)
1. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer.
Lopez A; Reyna DE; Gitego N; Kopp F; Zhou H; Miranda-Roman MA; Nordstrøm LU; Narayanagari SR; Chi P; Vilar E; Tsirigos A; Gavathiotis E
Nat Commun; 2022 Mar; 13(1):1199. PubMed ID: 35256598
[TBL] [Abstract][Full Text] [Related]
2. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Shi J; Zhou Y; Huang HC; Mitchison TJ
Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
4. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
5. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
6. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Li J; Chen Y; Wan J; Liu X; Yu C; Li W
Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
[TBL] [Abstract][Full Text] [Related]
7. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
8. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
[TBL] [Abstract][Full Text] [Related]
9. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
10. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis.
Shen Q; Li J; Mai J; Zhang Z; Fisher A; Wu X; Li Z; Ramirez MR; Chen S; Shen H
Cell Death Dis; 2018 Sep; 9(10):986. PubMed ID: 30250075
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
15. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Wong FY; Liem N; Xie C; Yan FL; Wong WC; Wang L; Yong WP
PLoS One; 2012; 7(12):e50786. PubMed ID: 23226540
[TBL] [Abstract][Full Text] [Related]
17. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
18. A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2.
Renault TT; Dejean LM; Manon S
Mech Ageing Dev; 2017 Jan; 161(Pt B):201-210. PubMed ID: 27112371
[TBL] [Abstract][Full Text] [Related]
19. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
